Active surveillance selection and 3-year durability in intermediate-risk prostate cancer following genomic testing. - Lenz L; Clegg W; Iliev D; Kasten CR; Korman H; Morgan TM; Hafron J; DeHaan A; Olsson C; Tutrone RF Jr; Richardson T; Cline K; et al. (Prostate cancer and prostatic diseases, 2025)